Jefferies downgraded Odonate Therapeutics from Buy to Hold and set a new price target of $4.00 from $45.00 previously

Cowen downgraded Odonate Therapeutics from Outperform to Market Perform

Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced that on January 6, 2022 it received written notice from The Nasdaq Stock Market LLC ("Nasdaq") notifying Odonate that Nasdaq believes that Odonate is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. Odonate will not appeal this determination. Therefore, Odonate expects the trading of its common stock on The Nasdaq Stock Market to be suspended at the opening of business on January 18, 2022, and that Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (the "SEC"), which will remove Odonate's securities from listing and registration on The

Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced that it will commence a share repurchase plan for up to 20 million shares in order to return capital to stockholders. This action is in connection with the Company's previously announced decision to discontinue the development of tesetaxel. Repurchases may be made from time to time at the Company's discretion. The plan has no time limit and can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases. As of September 30, 2021, as reported in its recently filed Form 10-Q, the Company had total stockholders' equity of $71.4 million, or $1.85 per share, based on 38.5 million shares ou

Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three and nine months ended September 30, 2021. As of September 30, 2021, Odonate had $95.0 million in cash compared to $157.3 million as of December 31, 2020. Odonate's cash used in operating activities for the three and nine months ended September 30, 2021 was $15.1 million and $63.0 million, respectively. Odonate's net loss for the three and nine months ended September 30, 2021 was $14.0 million and $69.8 million, or $0.37 and $1.85 per share, respectively, compared to $30.5 million and $94.1 million, or $0.93 and $3.00 per share, respectively, for the same periods in 2020. About Odonate Therapeutics, In

Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three and six months ended June 30, 2021. In March 2021, Odonate announced the discontinuation of development of tesetaxel and its intent to wind down tesetaxel-related operations. As of June 30, 2021, Odonate has transitioned all patients in tesetaxel studies to appropriate alternative therapies or facilitated continuation of treatment with tesetaxel under compassionate use programs where appropriate. As of June 30, 2021, Odonate had $110.1 million in cash compared to $157.3 million as of December 31, 2020. This decrease in cash resulted primarily from cash used in operating activities for the six months en

Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three months ended March 31, 2021. Odonate recently announced the discontinuation of development of tesetaxel and its intent to wind down tesetaxel-related operations. Odonate is working with clinical sites to transition patients in ongoing tesetaxel studies to appropriate alternative therapies or facilitate continuation of treatment with tesetaxel under compassionate use programs where appropriate. As of March 31, 2021, Odonate had $133.2 million in cash compared to $157.3 million as of December 31, 2020. This decrease in cash resulted primarily from cash used in operating activities for the three months en

NEW YORK--(BUSINESS WIRE)--Following feedback from the U.S. Food and Drug Administration (FDA) in a pre-New Drug Application meeting, Odonate Therapeutics, Inc. (NASDAQ: ODT) has concluded that the clinical data package for tesetaxel is unlikely to support FDA approval. Therefore, Odonate is discontinuing the development of tesetaxel and will wind down the operations of the Company. The Company will work with clinical sites to transition patients in ongoing tesetaxel clinical studies to appropriate alternative therapies. “We thank the investigators, study team personnel, and especially the patients and their caregivers for their endeavors to improve treatments for patients with bre

NEW YORK--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2020. As of December 31, 2020, Odonate had $157.3 million in cash, compared to $180.5 million as of December 31, 2019. This decrease in cash resulted primarily from cash used in operating activities for the twelve months ended December 31, 2020 of $113.1 million, partially offset by the receipt of $87.4 million of net proceeds from Odonate’s September 2020 underwritten public offering. Odon

NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Jeffrey Vacirca to its Board of Directors to help guide the company as it seeks commercial approval following announcement of positive Phase 3 data from the PROTECTIVE-2 study of plinabulin in combination with pegfilgrastim for protection against chemotherapy-induced neutropenia. “We are delighted to welcome Dr. Vacirca as a member of our Board of Directors, especially given his impressive leadership within the oncology community,” said Dr. Lan Huang, F

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best‑in‑class therapeutics that improve and extend the lives of patients with cancer, today announced that positive results from CONTESSA, a Phase 3 study of tesetaxel in patients with metastatic breast cancer (MBC), were presented in an oral presentation at the 2020 San Antonio Breast Cancer Symposium (SABCS). The results were presented by Joyce O’Shaughnessy, M.D., Celebrating Women Chair in Breast Cancer Research, Baylor University Medical Center, Texas Oncology and Chair, Breast Cancer Research, US Oncology, and Co‑Principal Investigator of CONTESSA (ple

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the initiation of Cohort 3 of CONTESSA TRIO, which will evaluate tesetaxel monotherapy in approximately 60 non-elderly patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Cohort 3 of CONTESSA TRIO will complement Cohort 2 of CONTESSA TRIO, which is evaluating tesetaxel monotherapy in approximately 60 elderly patients with HER2-negative MBC. Cohorts 2 and 3 of CONTESSA TRIO will expand on results from TOB203

SC 13G/A - Odonate Therapeutics, Inc. (0001717452) (Subject)

SC 13D/A - Odonate Therapeutics, Inc. (0001717452) (Subject)

SC 13D/A - Odonate Therapeutics, Inc. (0001717452) (Subject)

SC 13D/A - Odonate Therapeutics, Inc. (0001717452) (Subject)

SC 13G/A - Odonate Therapeutics, Inc. (0001717452) (Subject)

SC 13G - Odonate Therapeutics, Inc. (0001717452) (Subject)

SC 13G - Odonate Therapeutics, Inc. (0001717452) (Subject)

SC 13G/A - Odonate Therapeutics, Inc. (0001717452) (Subject)

SC 13G - Odonate Therapeutics, Inc. (0001717452) (Subject)

SC 13G/A - Odonate Therapeutics, Inc. (0001717452) (Subject)

4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

3 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

Gainers Bone Biologics Corporation (NASDAQ:BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ:ZNGA) rose 40.7% to settle at $8.44 after the company announced it will be acquired by Take-Two Interactive Software in a cash and stock transaction valued at $9.86 per Zynga share, representing a total enterprise value of approximately $12.7 billion. Molecular Partners AG (NASDAQ:MOLN) surged 30.5% to settle at $21.50 after the company, and Novartis, reported topline data from the Phase 2 study for ensovibep, a DARPin antiviral therapeutic for COVID-19. Reliance Global Group, Inc. (NASDAQ:RELI) climbed 28.9% to close at $7.86. Reliance Global Group, last month, announc

Gainers Hour Loop, Inc. (NASDAQ:HOUR) shares jumped 99.8% to $7.99 after the company priced its IPO at $4 per share. China HGS Real Estate Inc. (NASDAQ:HGSH) shares surged 57.5% to close at $3.48 on Friday. Traders may be viewing this stock as a play on a Friday deal by Papa John's to expand its presence in China by 1,350 stores. The Papa John's press release did not specifically mention a real estate company it would be working with for the expansion. ATA Creativity Global (NASDAQ:AACG) gained 33.3% to settle at $2.64. Marin Software Incorporated (NASDAQ:MRIN) shares jumped 31.3% to close at $4.53 on Friday after the company announced an integration with Amazon Ads' demand-side platfo

  Gainers Absci (NASDAQ:ABSI) stock increased by 28.2% to $7.87 during Friday's regular session. As of 12:30 EST, Absci's stock is trading at a volume of 38.6 million, which is 15366.1% of its average full-day volume over the last 100 days. The company's market cap stands at $728.6 million. Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 15.8% to $2.02. Trading volume for Quoin Pharmaceuticals's stock is 41.2 million as of 12:30 EST. This is 3934.9% of its average full-day volume over the last 100 days. The company's market cap stands at $16.8 million. Anixa Biosciences (NASDAQ:ANIX) shares increased by 15.06% to $3.36. Trading volume for this security as of 12:30 EST is 213

  Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana (NYSE:HUM) was the biggest company on a market cap basis to set a new 52-week low. Reshape Lifesciences (NASDAQ:RSLS) was the smallest firm on a market cap basis to set a new 52-week low. Aligos Therapeutics (NASDAQ:ALGS)'s stock moved significantly downwards, trading down 46.75% to reach a new 52-week low. Athenex (NASDAQ:ATNX) shares were the most resilient of the group, as shares actually moved up 0.0% in response to hitting its 52-week low. Stocks that set new 52-week lows during the first half-hour of trading on Friday are as follows: Humana (NYSE:HUM) stock hi

Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced that on January 6, 2022 it received written notice from The Nasdaq Stock Market LLC ("Nasdaq") notifying Odonate that Nasdaq believes that Odonate is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. Odonate will not appeal this determination. Therefore, Odonate expects the trading of its common stock on The Nasdaq Stock Market to be suspended at the opening of business on January 18, 2022, and that Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (the "SEC"), which will remove Odonate's securities from listing and registration on The N

    On Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows And Highs: Sea (NYSE:SE) is the largest company in terms of market cap to set a new 52-week low this morning. The smallest company by market cap to hit a new 52-week low was Reshape Lifesciences (NASDAQ:RSLS). Aligos Therapeutics (NASDAQ:ALGS) saw the largest move of the companies, as shares plummetted 46.75% to hit a new 52-week low. Vimeo (NASDAQ:VMEO) shares were the most resilient, as shares rose 0.0%, rebounding from its new 52-week low. The following stocks created new 52-week lows as of 10am on Thursday: Rivian Automotive (NASDAQ:RIVN) stock achieved a new 52-week low on Thursday morning, hitting $75

Gainers Aptinyx (NASDAQ:APTX) shares rose 4.72% to $2.66 during Wednesday's after-market session. Trading volume for this security closed at 80.2K, accounting for 49.36% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $180.1 million. iSpecimen (NASDAQ:ISPC) shares rose 4.24% to $14.75. The market value of their outstanding shares is at $128.5 million. Reshape Lifesciences (NASDAQ:RSLS) stock rose 3.96% to $2.1. The company's market cap stands at $7.3 million. Bluejay Diagnostics (NASDAQ:BJDX) stock rose 3.86% to $2.69. The market value of their outstanding shares is at $34.1 million. Odonate Therapeutics (NASDAQ:ODT) stock rose 3